Literature DB >> 9342192

Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient.

I N Bespalova1, S Adkins, M Pranzatelli, M Burmeister.   

Abstract

Two mutations in the cystatin B gene, a 3' splice mutation and a stop codon mutation, were previously found in patients with progressive myoclonus epilepsy of Unverricht-Lundborg type [Pennacchio et al. (1996): Science 271:1731-1734]. We present here a new mutation 2404deltaTC: a 2-bp deletion within the third exon of the cystatin B gene in an Unverricht-Lundborg patient. This mutation results in a frameshift and consequently premature termination of protein synthesis. Complete sequencing of the coding region and splice junctions of the cystatin B gene showed that neither of the two previously known mutations was present in this patient. The level of cystatin B mRNA in an immortalized cell line was found to be decreased, as had been reported for other Unverricht-Lundborg patients. The new mutation further supports the argument that defects in the cystatin B gene cause the Unverricht-Lundborg form of progressive myoclonus epilepsy. We describe a simple PCR method which can detect the 2404deltaTC deletion. This assay, together with previously described PCR assays for the other two known mutations, should prove useful in confirming clinically difficult diagnoses of Unverricht-Lundborg disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342192     DOI: 10.1002/(sici)1096-8628(19970919)74:5<467::aid-ajmg1>3.0.co;2-l

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  7 in total

Review 1.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

2.  Genetics of inherited human epilepsies.

Authors:  I Gourfinkel-An; S Baulac; A Brice; E Leguern; M Baulac
Journal:  Dialogues Clin Neurosci       Date:  2001-03       Impact factor: 5.986

3.  Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB.

Authors:  Véronique Brault; Benoît Martin; Nathalie Costet; Jean-Charles Bizot; Yann Hérault
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

4.  The role of initial oligomers in amyloid fibril formation by human stefin B.

Authors:  Ajda Taler-Verčič; Tiina Kirsipuu; Merlin Friedemann; Andra Noormägi; Mira Polajnar; Julia Smirnova; Magda Tušek Znidarič; Matjaž Zganec; Miha Skarabot; Andrej Vilfan; Rosemary A Staniforth; Peep Palumaa; Eva Zerovnik
Journal:  Int J Mol Sci       Date:  2013-09-05       Impact factor: 5.923

Review 5.  Cystatin C--properties and use as diagnostic marker.

Authors:  A O Grubb
Journal:  Adv Clin Chem       Date:  2000       Impact factor: 5.394

6.  Cystatins in immune system.

Authors:  Spela Magister; Janko Kos
Journal:  J Cancer       Date:  2012-12-20       Impact factor: 4.207

7.  Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer.

Authors:  Elena A Gashenko; Valentina A Lebedeva; Ivan V Brak; Elena A Tsykalenko; Galina V Vinokurova; Tatyana A Korolenko
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.